Cited 0 times in Scipus Cited Count

Effects of sarpogrelate on microvascular complications with type 2 diabetes

DC Field Value Language
dc.contributor.authorYoo, H-
dc.contributor.authorPark, I-
dc.contributor.authorKim, DJ-
dc.contributor.authorLee, S-
dc.date.accessioned2020-10-21T07:20:12Z-
dc.date.available2020-10-21T07:20:12Z-
dc.date.issued2019-
dc.identifier.issn2210-7703-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/18710-
dc.description.abstractBACKGROUND: Diabetes is a major cause of microvascular complications. Renin-angiotensin-aldosterone blockers have been known to have the benefits of delaying onset and progression of diabetic complications including nephropathy.
OBJECTIVE: To evaluate the effect of sarpogrelate, an antiplatelet agent, on the new onset diabetic complications in patients with type 2 diabetes mellitus.
SETTING: A 1108-bed tertiary university hospital in Korea.
METHODS: A retrospective cohort study was conducted using electronic medical records between 2010 and 2015 in Korea. The study cohort of the propensity score matched patients with or without sarpogrelate was evaluated for the diabetic complications identified with the diagnosis codes in T2DM patients on the metformin based antidiabetic therapy. Nephropathy was further evaluated for progression of kidney function. Main outcome measure The incidence of composite microvascular complications included nephropathy, neuropathy, and retinopathy.
RESULTS: The 1:2 propensity score matched 478 out of 14,440 patients were included in the final analysis with or without sarpogrelate (162 vs. 316 patients). The incidence of nephropathy, neuropathy, and retinopathy was 1.23% versus 5.38% (HR 0.21, 95% CI 0.05-0.92), 1.23% versus 4.43% (HR 0.26, 95% CI 0.06-1.14), and 6.17% versus 6.33% (HR 0.93, 95% CI 0.43-1.97) with sarpogrelate and without sarpogrelate, respectively. Changes in the estimated glomerular filtration rate and urine albumin creatinine ratio were not significantly different between the groups.
CONCLUSION: In Korean patients, sarpogrelate, an antiplatelet agent, was associated with reducing the incidence and progression of nephropathyin type 2 diabetes, but not associated with the composite endpoints including neuropathy and retinopathy.
-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHDiabetes Mellitus, Type 2-
dc.subject.MESHDiabetic Angiopathies-
dc.subject.MESHDiabetic Nephropathies-
dc.subject.MESHDiabetic Neuropathies-
dc.subject.MESHDiabetic Retinopathy-
dc.subject.MESHElectronic Health Records-
dc.subject.MESHFemale-
dc.subject.MESHHospitals, University-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSuccinates-
dc.titleEffects of sarpogrelate on microvascular complications with type 2 diabetes-
dc.typeArticle-
dc.identifier.pmid30864083-
dc.subject.keywordDiabetic complications-
dc.subject.keywordKorea-
dc.subject.keywordNephropathy-
dc.subject.keywordNeuropathy-
dc.subject.keywordRetinopathy-
dc.subject.keywordSarpogrelate-
dc.contributor.affiliatedAuthor박, 인휘-
dc.contributor.affiliatedAuthor김, 대중-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s11096-019-00794-7-
dc.citation.titleInternational journal of clinical pharmacy-
dc.citation.volume41-
dc.citation.number2-
dc.citation.date2019-
dc.citation.startPage563-
dc.citation.endPage573-
dc.identifier.bibliographicCitationInternational journal of clinical pharmacy, 41(2). : 563-573, 2019-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn2210-7711-
dc.relation.journalidJ022107703-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nephrology
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse